Dr Chris Jolly
C39 - Royal Prince Alfred Hospital
On this page
PhD: Macquarie University/CSIRO, Sydney - 1993
Postdoctoral Fellow, John Curtin School of Medical Research, ANU, Canberra - 1993-1994 Postdoctoral Fellow: MRC Laboratory of Molecular Biology, Cambridge, UK - 1995-1997 Group Leader, Centenary Institute, Sydney - 1998-present[Hide detail]
My group studies antibody mutation in activated B cells, which is initiated by the DNA editing enzyme "AID". B cells mutate their antibody genes at extremely high rates during infections, to rapidly optimise the ability of the antibodies they make to neutralise the infecting pathogen. "Off-target" mutation of oncogenes by AID underlies most adult B cell cancers, so we seek to understand why AID-induced DNA damage leads to mutation, when similar DNA damage is generally repaired faithfully.
B cell development. Antibody gene rearrangement and mutation.
Current national competitive grants*
Regulation of the quality of DNA repair by timing in the cell cycle
National Health and Medical Research Council Project Grant ($452,957 over 3 years)
* Grants administered through the University of Sydney